Daxor (NASDAQ:DXR) Given New $25.00 Price Target at Ascendiant Capital Markets

Daxor (NASDAQ:DXR) had its price objective upped by Ascendiant Capital Markets from $24.75 to $25.00 in a research report report published on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Daxor Stock Down 2.6 %

DXR stock opened at $7.97 on Monday. The company has a fifty day moving average price of $7.79 and a two-hundred day moving average price of $8.48. Daxor has a one year low of $6.55 and a one year high of $10.00.

Insiders Place Their Bets

In related news, CEO Michael Richard Feldschuh acquired 3,360 shares of Daxor stock in a transaction on Monday, March 10th. The stock was purchased at an average cost of $7.68 per share, with a total value of $25,804.80. Following the completion of the transaction, the chief executive officer now directly owns 210,852 shares in the company, valued at $1,619,343.36. This trade represents a 1.62 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 59.00% of the company’s stock.

Institutional Investors Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC grew its holdings in Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 as of its most recent SEC filing. 1.34% of the stock is currently owned by hedge funds and other institutional investors.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.